Clinical trial
A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN)
NCT04408625 is registered in ClinicalTrials.gov with Prevail Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN)
- Lead sponsor
- Prevail Therapeutics
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- November 9, 2020
- Completion date
- November 30, 2029
- Enrollment
- 35 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.